Recent Updates
Recently added Catalysts
NVCR Negative Sentiment Score: 30/100

NOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR

Key Takeaway: Kahn Swick & Foti, LLC has announced a reminder for investors of NovoCure Limited that they have until August 18, 2023, to file lead plaintiff applications in a class action lawsuit over allegations of failing to disclose material information. This comes after NovoCure's announcement of positive Phase 3 LUNAR trial results, which saw a significant stock price decline of 43.04%. The legal action will be overseen by the United States District Court for the Southern District of New York, highlighting serious investor concerns regarding compliance with federal securities laws.

Market Sentiment Analysis

POSITIVE FACTORS

  • NovoCure announced positive results from the Phase 3 LUNAR trial.
  • The therapy shows potential for treating non-small cell lung cancer.

CONCERNS & RISKS

  • Shares of NovoCure fell by 43.04% following the announcement.
  • The therapy was tested on patients who worsened after chemotherapy, not reflective of current standards.

Full Press Release Details

NEW ORLEANS, June 27, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 18, 2023 to file lead plaintiff applications in a securities class action lawsuit against NovoCure Limited (NasdaqGS: NVCR), if they purchased the Company’s securities between January 5, 2023 to June 5, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
If you purchased securities of NovoCure and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-nvcr/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 18, 2023.
NovoCure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 6, 2023, the Company announced “positive results” from the Phase 3 LUNAR clinical trial evaluating the use of its Tumor Treating Fields therapy together with standard therapies for the treatment of non-small cell lung cancer; however, despite some positive aspects to the news, analysts noted that the therapy was tested in patients who worsened following chemotherapy, which is no longer the standard of care in lung cancer, and that most patients first receive immune checkpoint inhibitors.
On this news, shares of NovoCure fell $35.51 per share, or 43.04%, to close at $47.00 per share on June 6, 2023.
The case is Bazzelle v. NovoCure Limited, et al., No. 23-cv-5146.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit http://ksfcounsel.com/.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline for filing lead plaintiff applications?

The deadline to file lead plaintiff applications is August 18, 2023.

What class action is KSF involved in against NovoCure?

KSF is involved in a securities class action against NovoCure for failing to disclose material information.

How did NovoCure's stock react to recent news?

NovoCure shares dropped by 43.04% to $47.00 after announcing clinical trial results.

What is the main allegation against NovoCure executives?

NovoCure executives are charged with violating federal securities laws by not disclosing critical information.

How can I contact KSF for legal concerns?

You can contact KSF Managing Partner Lewis Kahn at 1-877-515-1850 or via email.

Last updated: Jun 28, 2023